{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:26:50Z","timestamp":1789165610327,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ebiom.2022.103906","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T07:02:13Z","timestamp":1646377333000},"page":"103906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Achieving virological control in pan-resistant HIV-1 infection: A case series"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7962-7193","authenticated-orcid":false,"given":"Diana","family":"Canetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Muccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Spagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Gianotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Feasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.103906_bib0001","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ebiom.2022.103906_bib0002","doi-asserted-by":"crossref","first-page":"S798","DOI":"10.1093\/infdis\/jix137","article-title":"Global HIV antiretroviral drug resistance: a perspective and report of a national institute of allergy and infectious diseases consultation","volume":"216","author":"Godfrey","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ebiom.2022.103906_bib0003","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human immunodeficiency virus drug resistance: 2018 recommendations of the international antiviral society-USA panel","volume":"68","author":"G\u00fcnthard","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2022.103906_bib0004","unstructured":"European AIDS Clinical Society Guidelines for treatment of people living with HIV. EACS Guidelines version 10.1, October 2020. https:\/\/www.eacsociety.org\/files\/guidelines-10.1_30032021_1.pdf Accessed 28th June, 2021."},{"key":"10.1016\/j.ebiom.2022.103906_bib0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/hiv.12411","article-title":"Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe","volume":"18","author":"Judd","year":"2017","journal-title":"HIV Med"},{"key":"10.1016\/j.ebiom.2022.103906_bib0006","article-title":"Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database","volume":"28","author":"Lombardi","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ebiom.2022.103906_bib0007","doi-asserted-by":"crossref","first-page":"ofaa456","DOI":"10.1093\/ofid\/ofaa456","article-title":"Burden of disease in PWH harboring a multidrug-resistant virus: data from the PRESTIGIO registry","volume":"7","author":"Galli","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ebiom.2022.103906_bib0008","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2666-5247(20)30006-9","article-title":"Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report","volume":"1","author":"Puertas","year":"2020","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ebiom.2022.103906_bib0009","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.ebiom.2022.103906_bib0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/QAI.0000000000002147","article-title":"Brief report: association between low HIV-1 DNA and western blot reactivity to HIV-1 pol in chronically infected individuals","volume":"82","author":"Muccini","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ebiom.2022.103906_bib0011","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/QAI.0b013e3181a56f46","article-title":"Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure","volume":"51","author":"Cossarini","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ebiom.2022.103906_bib0012","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1128\/JVI.02154-08","article-title":"In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine","volume":"83","author":"Parades","year":"2009","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103906_bib0013","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3018(17)30069-3","volume":"4","author":"Ciaffi","year":"2017","journal-title":"Lancet HIV"},{"issue":"10","key":"10.1016\/j.ebiom.2022.103906_bib0014","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/jac\/dkx233","article-title":"HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir\u2009+\u2009lamivudine in the maintenance DOLULAM pilot study","volume":"72","author":"Charpentier","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.ebiom.2022.103906_bib0015","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/aid.2014.0124","article-title":"Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent","volume":"30","author":"Cavarelli","year":"2014","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.ebiom.2022.103906_bib0016","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.103906_bib0017","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QAI.0000000000002241","article-title":"Clinical and economic impact of ibalizumab for people with multidrug-resistant HIV in the United States","volume":"83","author":"Millham","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ebiom.2022.103906_bib0018","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcv.2018.04.001","article-title":"Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment","volume":"104","author":"Armenia","year":"2018","journal-title":"J Clin Virol"},{"key":"10.1016\/j.ebiom.2022.103906_bib0019","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1097\/QAI.0000000000002378","article-title":"Simplification to high genetic barrier 2-drug regimens in people living with HIV harboring 4-class resistance enrolled in the PRESTIGIO registry","volume":"84","author":"Canetti","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ebiom.2022.103906_bib0020","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in adults with multidrug-resistant HIV-1 infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.103906_bib0021","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1016\/S2352-3018(20)30240-X","article-title":"Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study","volume":"7","author":"Lataillade","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ebiom.2022.103906_bib0022","article-title":"Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc","author":"Ronald","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.ebiom.2022.103906_bib0023","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1128\/JVI.02237-10","article-title":"Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4+ antibody ibalizumab","volume":"85","author":"Toma","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.ebiom.2022.103906_bib0024","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.00761-05","article-title":"Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4+ antibody (TNX-355) and enfuvirtide (T-20)","volume":"50","author":"Zhang","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ebiom.2022.103906_bib0025","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/AAC.00942-08","article-title":"Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4+ monoclonal antibody, in human immunodeficiency virus type 1-infected adults","volume":"53","author":"Jacobson","year":"2009","journal-title":"Antimicrob Agents Chemother"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422000901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422000901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:14:47Z","timestamp":1762456487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422000901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":25,"alternative-id":["S2352396422000901"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.103906","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achieving virological control in pan-resistant HIV-1 infection: A case series","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.103906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103906"}}